The Role of Lymphadenectomy in Cervical Cancer Patients: The Significance of the Number and the Status of Lymph Nodes Removed in 526 Cases Treated in a Single Institution
- 28 June 2013
- journal article
- clinical trial
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 20 (12) , 3948-3954
Abstract
To investigate whether the total number of removed lymph nodes (LNs) and the number of metastatic LNs would prove to be independent prognostic factors for survival in patients with cervical cancer (CC). Data from patients with CC who underwent radical surgery between March 1980 and September 2009 were reviewed. A total of 526 patients were included in the statistical analysis. Full pathologic evaluation was performed. The total number of examined LNs and their histopathological status were analyzed for their prognostic effect on survival by means of multivariable Cox proportional hazard regression models. The median number (interquartile range) of total, pelvic, and para-aortic nodes removed was 37 (29–47), 34 (27–42), and 19 (14–24), respectively. Positive pelvic nodes were found in 102 of 526 (19 %) patients. All 8 patients with para-aortic metastases had also pelvic node metastases. At multivariable analysis, vaginal involvement, type of lymphadenectomy and LN status all significantly negatively affected disease-free survival and overall survival, whereas the number of total LNs removed did not affect survival. LN metastasis and number of LN metastases confer an independent risk for worse survival in patients with CC. Pelvic lymphadenectomy is important for staging and regional disease control when LNs are involved. If a standardized complete lymphadenectomy is performed, the number of LNs is not a significant factor per se.Keywords
This publication has 15 references indexed in Scilit:
- Weekly topotecan and cisplatin (TOPOCIS) as neo-adjuvant chemotherapy for locally-advanced squamous cervical carcinoma: Results of a phase II multicentric studyEuropean Journal of Cancer, 2013
- Class I versus class III radical hysterectomy in stage IB1-IIA cervical cancer. A prospective randomized studyEuropean Journal of Surgical Oncology, 2012
- Therapeutic role of lymphadenectomy for cervical cancerCancer, 2010
- Quality assurance for radical hysterectomy for cervical cancer: the view of the European Organization for Research and Treatment of Cancer—Gynecological Cancer Group (EORTC-GCG)Annals of Oncology, 2009
- A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative StudyAnnals of Oncology, 2009
- Up-to-date management of lymph node metastasis and the role of tailored lymphadenectomy in cervical cancerInternational Journal of Clinical Oncology, 2007
- The number of pelvic lymph nodes in the quality control and prognosis of radical hysterectomy for the treatment of cervical cancerEuropean Journal of Surgical Oncology, 2007
- Carcinoma of the Cervix UteriInternational Journal of Gynecology & Obstetrics, 2006
- A Randomized Trial of Pelvic Radiation Therapy versus No Further Therapy in Selected Patients with Stage IB Carcinoma of the Cervix after Radical Hysterectomy and Pelvic Lymphadenectomy: A Gynecologic Oncology Group StudyGynecologic Oncology, 1999
- Prognostic Factors and Impacts of Adjuvant Therapy in Early-Stage Cervical Carcinoma with Pelvic Node MetastasesGynecologic Oncology, 1993